← Back to Clinical Trials
Recruiting NCT05642832

NCT05642832 Feasibility of Reducing Respiratory Drive Using the Through-flow System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05642832
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Respiratory Insufficiency
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2024-01-01
Primary Completion 2025-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Throughflow titration phase

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2024-01-01 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mechanical ventilation can lead to diaphragm and lung injury. During mechanical ventilation, the diaphragm could be completely rested or it could be overworked, either of which may cause diaphragm injury. Mechanical stress and strain applied by mechanical ventilation or by the patient's own respiratory muscles can also cause injury to the lungs. Diaphragm and lung injury are associated with increased morbidity and mortality. Throughflow is a novel system that can reduce dead space without the need to increase the tidal ventilation, reducing the ventilatory demands and respiratory drive.

Eligibility Criteria

Inclusion Criteria: * PaO2/FiO2 less than or equal to 300 at time of screening * Oral endotracheal intubation with ETT 7.5 or 8.0 and on invasive mechanical ventilation * Bilateral airspace opacities on chest radiograph or chest CT scan Exclusion Criteria: * Contraindication to esophageal catheterization (upper gastrointestinal tract surgery within preceding 6 weeks, bleeding esophageal/gastric varices) * Intubation for traumatic brain injury or stroke * Intracranial hypertension (suspected or diagnosed by medical team) * Anticipated liberation from mechanical ventilation within 24 hours

Contact & Investigator

Central Contact

Rongyu ( Cindy) Jin

✉ rongyu.jin@uhn.ca

📞 4163404800

Principal Investigator

Ewan Goligher, MD, PhD

PRINCIPAL INVESTIGATOR

University Health Network, Toronto

Frequently Asked Questions

Who can join the NCT05642832 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05642832 currently recruiting?

Yes, NCT05642832 is actively recruiting participants. Contact the research team at rongyu.jin@uhn.ca for enrollment information.

Where is the NCT05642832 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT05642832 clinical trial?

NCT05642832 is sponsored by University Health Network, Toronto. The principal investigator is Ewan Goligher, MD, PhD at University Health Network, Toronto. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology